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The progressive loss of muscle mass characteristic of many muscular dystrophies impairs
the efficacy of most of the gene and molecular therapies currently being pursued for
the treatment of those disorders. It is becoming increasingly evident that a therapeutic
application, to be effective, needs to target not only mature myofibers, but also muscle
progenitors cells or muscle stem cells able to form new muscle tissue and to restore
myofibers lost as the result of the diseases or during normal homeostasis so as to
guarantee effective and lost lasting effects. Correction of the genetic defect using
oligodeoxynucleotides (ODNs) or engineered nucleases holds great potential for the
treatment of many of the musculoskeletal disorders. The encouraging results obtained
by studying in vitro systems and model organisms have set the groundwork for what is
likely to become an emerging field in the area of molecular and regenerative medicine.
Furthermore, the ability to isolate and expand from patients various types of muscle
progenitor cells capable of committing to the myogenic lineage provides the opportunity
to establish cell lines that can be used for transplantation following ex vivo manipulation
and expansion. The purpose of this article is to provide a perspective on approaches
aimed at correcting the genetic defect using gene editing strategies and currently under
development for the treatment of Duchenne muscular dystrophy (DMD), the most sever
of the neuromuscular disorders. Emphasis will be placed on describing the potential of
using the patient own stem cell as source of transplantation and the challenges that gene
editing technologies face in the field of regenerative biology.
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INTRODUCTION
The discovery of dystrophin as the gene responsible for Duchenne
muscular Dystrophy (DMD) has enabled researchers to identify
several of the genes linked directly or indirectly to dystrophin and
to correlate defects in those genes to many of the different forms
of muscular dystrophies (Monaco et al., 1986; Hoffman et al.,
1987; Koenig et al., 1987). Despite the diversity in phenotypic
and pathological manifestation of various forms of muscular dys-
trophies identified to date, many display common symptoms.
Characteristic is the progressive loss of muscle mass which has
been attributed, at least in part, to the inability of muscle stem
cells to efficiently regenerate tissue lost as the result of the dis-
ease. Great progress has been made toward the identification
of therapies for DMD. Potential approaches range from gene
augmentation strategies using viral or plasmid vectors aimed at
restoring dystrophin expression to upregulation of genes that
could be used to overcome the lack of expression of the defected
gene. While some of these approaches have sown efficacy, the
results obtained to date have also expounded limitations in the
clinical applicability of therapeutic applications to DMD. In par-
ticular, the progressive loss of expression of the therapeutic gene
observed following treatment have clearly indicated that targeting
mature myofibers alone is not sufficient to preserve the beneficial
effects achieved by the therapeutic approach (Bertoni et al., 2006;
Kayali et al., 2010). Critical to the development of effective strate-
gies to treat muscle disorders is the optimization of approaches
targeting muscle stem cells and capable of regenerating tissue
lost as the result of the disease or as the result of normal muscle
turnover.
Muscle stem cells are classically defined as undifferentiated
cells characterized by their unique ability to activate in response
to specific stimuli and self-renew. Daughter cells originated by the
division of stem cells can either retain their stem cell identity or
differentiate into a more committed lineage capable of producing
new muscle tissue or of fusing with preexisting myofibers to
repair damage ones. Among the different types and subtypes
of muscle stem cells identified to date, satellite cells (SCs) are
probably the most studied. Since their initial identification
(Mauro, 1961) studies have clearly demonstrated that SCs are
composed by an heterogeneous population of muscle stem cells
distinguishable based on their gene expression signatures, their
ability to commit into a specific myogenic lineage, their capacity
to assume non-myogenic cell-fate and differences in their ability
to activate in response to specific queues (Schultz, 1996; Seale
et al., 2000; Ono et al., 2010; Bentzinger et al., 2012; Brack and
Rando, 2012; Yin et al., 2013). Other types of stem cells capable
of assuming a myogenic cell fate and of regenerating mus-
cles have been described. Those include bone marrow stem cells
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(Ferrari et al., 1998; Bittner et al., 1999; Gussoni et al., 1999), mus-
cle side population (SP) cells (Gussoni et al., 1999; Asakura et al.,
2002; Rivier et al., 2004; Doyle et al., 2011), muscle-derived
stem cells (Lee et al., 2000), mesangioblasts (Minasi et al., 2002;
Sampaolesi et al., 2003; Galli et al., 2005; Morosetti et al., 2006),
pericytes (Dellavalle et al., 2007; Peault et al., 2007), embryonic
stem cells (ESCs) (Bhagavati and Xu, 2004; Barberi et al., 2007;
Darabi et al., 2009; Filareto et al., 2012) and induced pluripotent
stem cells (iPSCs) (Chang et al., 2009; Kazuki et al., 2010; Darabi
et al., 2012; Tedesco et al., 2012).
Therapeutic approaches to muscle disorders and targeting
stem cells have focused primarily on demonstrating the feasibil-
ity of restoring dystrophin expression following transplantation
of cells isolated from healthy donors. Proof-of-concept studies
have been performed in immunosuppressed mdx mice that have
been used as models for DMD (Coulton et al., 1988; Sicinski et al.,
1989). Some success has been achieved using transplantation of
freshly isolated SCs (Collins et al., 2005; Boldrin et al., 2009, 2012)
or subpopulations of SCs isolated using fluorescence activate cell
sorting (FACS) which have been used primarily to demonstrate
the existence of distinguished populations of SCs with regener-
ative capacity and capable of self-renewing (Cerletti et al., 2008;
Sacco et al., 2008; Rocheteau et al., 2012).
Despite the encouraging results obtained to date in the field,
issues still remain that may hamper the applicability of cell-
mediated regenerative approaches to muscle disorders. Among
those, is the need to use heterologous sources for the transplan-
tation procedure and the risk of immune rejection associated
with their use. The issue of immune response could be overcome
by the use of reprogrammable stem cells capable of differentiate
into muscle progenitor cells such as human ESCs human iPSCs
(Darabi et al., 2012) or mesoangioblasts (Tedesco et al., 2012)
isolated directly from the patient and that have been genetically
modified to express dystrophin or other therapeutically relevant
genes. Among the technologies currently being investigated for
the treatment of DMD, gene editing is perhaps the most excit-
ing as it offers the possibility to correct a genetic defect at the
source of the problem, the DNA and can therefore promise to
restore a completely functional protein. Critical to the success
of gene editing strategies for muscle disorders is to target cells
capable of retaining the stem cells properties to ensure that the
beneficial effects achieved by the gene correction process is main-
tained over time. As such, the use of muscle stem cells capable of
self-renewing is likely to have advantages over other type of cells,
namely due to their ability to actively participate to the regenera-
tive process over prolonged periods of time with virtually little or
no loss of regenerative potential.
The use of gene editing in muscle stem cells for therapeutic
purposes can be divided into two major applications: strategies
aimed at targeting muscle stem cells ex vivo that can be used for
transplantation purposes and strategies aimed at targeting and
correcting stem cells in situ following systemic administration of
the therapeutic agent into the patient’s own stem cells, mainly SCs
(Figure 1). Both approaches present pros and cons as discussed
in more detail below (see Drawbacks and limitations of gene edit-
ing mediated by ODNs and endonucleases). Among the hurdles
that will need to be overcome before cell-mediated therapies can
be brought into the clinic is the need to target a large number
of muscles for the therapy to be clinically relevant. Nonetheless,
the use of gene editing strategies in muscle stem cells is likely
to become a valid therapeutic alternative to gene augmentation
therapies. This review will provide an overview of the progress
made in the past decade toward the development of gene editing
tools for the treatment of DMD and the current state-of-the art
of technologies aimed at permanently correct the genetic defect
in muscle progenitor cells and stem cells.
OLIGONUCLEOTIDE-MEDIATED GENE CORRECTION
Different areas of investigations have focused on the possibility of
using oligodeoxynucleotides (ODNs) as therapeutic vectors. First
among those, the success obtained using homologous recombi-
nation (HR) technologies, an approach that has been employed
extensively to generate animal models to study disease mech-
anisms (Capecchi, 1989). However, the low frequency of HR
and the high frequency of non-homologous integration of such
constructs have clearly evidenced serious limitations in the appli-
cability of this approach for the treatment of inherited diseases
and have prompted the development of new, safer vectors capa-
ble of activating repair mechanisms other than HR and capable
of introducing single base pair (bp) alterations at the genomic
DNA without the need of integrating into the genome. Gene edit-
ing mediated by ODNs generally employs short (less than 100
nucleotides) synthetic DNA or RNA sequences homologous to
the region of the genomic DNA targeted for repair. The technol-
ogy differ substantially from that employing antisense oligonu-
cleotides (AONs), that also uses oligonucleotides, but that act at
the messenger RNA (mRNA) level to block and therefore redirect
splicing of the mRNA to produce shorter although still functional
proteins (Arechavala-Gomeza et al., 2012). Gene editingmediated
by ODNs takes advantage of innate repair mechanisms present
in the cell and responsible for maintenance of chromosome
integrity. The process requiresmultiple steps which begin with the
pairing of the ODN with the region of the genomic DNA targeted
for repair, recognition of the mismatch on the targeted base, exci-
sion of the mutation, and insertion of the desired base (Figure 2).
EVOLUTION OF ODNs FOR GENE EDITING PURPOSES
The initial vectors employed for gene editing strategies consisted
of chimeric DNA/RNA ODNs (chODNs) made of 68 residues
which were originally given the name of chimeraplasts. The vec-
tor contained both RNA and DNA residues complementary to
the region of the genomic DNA targeted for repair and flanked
by 2′-O-methylated RNA residues which were used to increase
resistance to RNase H activity (Figure 2A). To increase stability
and maintain their secondary structure, ODNs were designed to
contain at their 3′ and 5′ ends polythymidine hairpins and a 3′
tag containing a clamp made of guanidine and cytosine residues
(Figure 2A) (Cole-Strauss et al., 1996; Kren et al., 1999a,b;
Bertoni, 2008). These chODNs were designed to pair with both
strands of the gene targeted for repair and to activate DNA mis-
match repair (MMR) mechanisms though the recognition of the
single base mismatch present on the ODN (Figure 2B). The acti-
vation results in the conversion of the targeted base at the genomic
level using the information provided by the chODN. Since their
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FIGURE 1 | Cell-mediated regenerative approaches to muscle disorders.
Gene editing strategies in muscle stem cells are aimed at either correcting
the genetic disorder ex vivo or at delivery the therapeutic agent in situ
following systemic administration. (A) Ex vivo approaches requires harvesting
of cells from the patient or healthy donor, reprogramming in cases were the
cells being employed are not muscle-derived, editing using the targeting
tools, selection of the cells undergone repair and expansion prior to delivery
into muscle through local, or systemic administration. (B) Delivery of the
gene editing tools into muscle typically uses the circulatory system and can
employ intraperitoneal, subcutaneous, intra-arterial, or intravenous
administration depending on the physico-chemical, and pharmacological
properties of the therapeutic agent being employed. The method is much
less invasive than direct intramuscular injection and has the potential of
targeting a large number of muscles simultaneously.
first application, chODNs have been investigated in their ability to
target and induce genomic modifications in a number of different
cell types and have been successfully applied in both eukaryotic
and prokaryotic cells (Cole-Strauss et al., 1996, 1999; Kren et al.,
1998, 1999b; Beetham et al., 1999; Zhu et al., 1999, 2000; Bartlett
et al., 2000; Rando et al., 2000; Rice et al., 2000, 2001; Tagalakis
et al., 2001; Igoucheva and Yoon, 2002).
The initial studies exploring the feasibility of using chODNs
for the treatment of muscular dystrophies were performed in the
mdx mouse model for DMD (Rando et al., 2000; Bertoni and
Rando, 2002; Bertoni et al., 2003). A chODN designed to tar-
get and correct the single point mutation present in exon 23 of
the dystrophin gene was shown to restore dystrophin expression
in both muscle precursor cells in culture (Bertoni and Rando,
2002) as well as in vivo following direct intramuscular injection
(Rando et al., 2000). Importantly, correction was demonstrated
to be stably inherited in dividing cells and to result in restoration
of full-length dystrophin expression. When administered intra-
muscularly at high doses, the chODN was able to distribute into
approximately 40% of the SCs present in the muscle (Bertoni
and Rando, 2002). Once explanted, SCs that had taken up the
chODN targeting the mdx mutation, were shown to proliferate
and expand in vitro to produce myoblasts capable of differen-
tiating and to form myotubes which expressed full-length dys-
trophin. The level of gene repair detected in those cells remained
substantially lower than that achieved in muscle progenitor cells
transfected with the targeting chODN in culture demonstrat-
ing the presence of intrinsic differences in the ability of SCs to
undergo gene repair compared to myoblasts (Bertoni and Rando,
2002). Nonetheless, the results clearly indicated the feasibility of
using ODNs to target and correct SCs and demonstrated for the
first time the possibility of targeting SCs in situ following delivery
of ODNs. Studies in the GRMD have confirmed the feasibility of
using chODNs to correct defects in the dystrophin gene in larger
animals (Bartlett et al., 2000).
A key advancement in vector development was the discovery
that ODNs made of single stranded DNA sequences (ssODNs)
were as efficient as chODNs in directing the gene correction pro-
cess (Gamper et al., 2000a,b) rendering this technology widely
available to virtually any laboratory interested in exploring its
potential application in different prokaryotic and eukaryotic sys-
tems and for different applications (Igoucheva et al., 2001, 2008;
Dekker et al., 2003, 2006; Nickerson and Colledge, 2003; Pierce
et al., 2003; Radecke et al., 2004; Bertoni et al., 2005; Olsen et al.,
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FIGURE 2 | ODN-mediated gene editing. (A) The basic structure of
targeting ODNs consists of a stretch of DNA perfectly homologous to the
region of the gene that is targeted for correction with the exception of a
single base mismatch. A chODN contains a complimentary region
composed of 2′-O-methyl RNA interrupted by a pentameric block of DNA
bases while ssODNs consist of unmodified DNA bases and can be
complimentary to the coding strand or complimentary to the non-coding
strand of the gene targeted for correction. Phosphorothioate (PS) bases
are added to the each end of the ODNs to increase their stability to
endonucleases. (B) The correction process is activated by the pairing of
ODN with the genomic sequence targeted for repair. Recognition of the
mismatch present on the ODNs activates innate repair mechanisms
naturally present in the cell nuclei and capable of directing the correction
based on the information provided by the ODN template. The process
require the presence of protein such as RecA and MSH2 capable of
recognizing and correct the mismatch.
2005b; Sorensen et al., 2005; Aarts et al., 2006; Morozov and
Wawrousek, 2008; Disterer et al., 2009). ssODN can either be
complementary to the leading strand of the genomic loci or com-
plimentary to the lagging strand (Figure 2A). In muscle, gene
correctionmediated by ssODNhas been assessed using themdx5cv
mouse. In this model, an A-to-T transversion in exon 10 of the
dystrophin gene creates a cryptic splice site recognized by the
splicing machinery. Thus, the mRNA of the dystrophin gene is
aberrantly spliced causing total absence of dystrophin (Im et al.,
1996). The use of the mdx5cv mouse allows to precisely quan-
titate frequencies of gene repair achieved at both, the genomic
DNA and mRNA levels, making this animal model particularly
valuable (Bertoni et al., 2005; Kayali et al., 2010). Results clearly
indicated that ssODNs complementary to the coding strand were
as effective as chODN in correcting the dystrophin gene defect
in mdx5cv in vitro as well as in vivo. A strand bias was observed
in the correction abilities of linear DNA ODNs depending on
whether the ssODNs were targeting the coding or the non-coding
strand of the dystrophin gene, suggesting that transcription may
influence the ability of ssODNs to induce the genetic alteration
at the chromosome level (Bertoni et al., 2005). Differences in
strand bias observed by others seem to confirm the implication of
transcription in the processes that take place in gene repair medi-
ated by ssODNs (Igoucheva et al., 2001, 2003; Liu et al., 2001,
2002).
In recent years, studies have focused primarily on identifying
new generation of ssODNs that could promote more efficiently
the repair process in an effort to increase the frequencies of gene
repair to levels that would be considered therapeutically relevant.
Some success has been obtained by increasing the stability of the
ODNs. The use of ssODNs containing 2′-O-methyl RNA residues
(Igoucheva et al., 2001; Nickerson and Colledge, 2003), PS link-
ages (Liu et al., 2002; Olsen et al., 2005b), or Locked Nucleic Acid
(LNA) bases (Parekh-Olmedo et al., 2002) at their extremities
have been shown to increase targeting frequencies. Several studies
have also demonstrated that gene repair can be enhanced by syn-
chronizing the cells in the S phase of the cell cycle or by reducing
the rate of replication fork progression (Brachman and Kmiec,
2004; Ferrara and Kmiec, 2004; Ferrara et al., 2004; Olsen et al.,
2005a). Promising results have been achieved in muscle using
ssODNsmade of peptide nucleic acids (PNAs) bases (Kayali et al.,
2010). PNAs are DNA mimics capable of forming stable duplex
structures with Watson-Crick complementary DNA or RNA with
a higher binding affinity than that of DNA/DNA or DNA/RNA
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duplexes made of unmodified bases (Nielsen, 2005). In general,
ssODNs stretching from 12 to 18 nucleotides are sufficient to
allow strong duplex formation with their complementary DNA or
RNA sequences and to distinguish single base mutations. Kayali
et al demonstrated that ssODNs made of PNA (PNA-ssODNs)
containing the appropriate mismatch were capable of targeting
and correcting the mdx5cv mutation in the dystrophin gene more
efficiently than ssODNs made of unmodified bases (Kayali et al.,
2010). Expression of full-length dystrophin was sustained for up
to four months after injection although correction was shown to
decrease over time as the result of normal muscle turnover (Kayali
et al., 2010). These results were particularly important to the field
fo gene editing for DMD because provided the first evidence of
how correction of the genetic defect in mature myofibers alone
is not sufficient to guarantee long lasting effects and paved the
way for subsequent studies aimed at studying the feasibility of tar-
geting and correcting SCs and their therapeutic relevance for the
treatment of DMD.
MECHANISMS OF ACTION OF ODN-MEDIATED GENE REPAIR
It is believed that chODNs and ssODNs act through similar
mechanisms and that the repair process involves multiple steps
(Gamper et al., 2000a,b; Igoucheva et al., 2004). The first steps
requires the annealing of the ODN to the region of the genomic
DNA targeted for repair (Liu et al., 2003; Jensen et al., 2011;
Papaioannou et al., 2012). Pairing leads to the formation of a het-
eroduplex between the ssODN and the double-stranded target site
(Figure 2B) (Bertoni, 2005, 2008; Engstrom et al., 2009). Msh2, a
member of the family of proteins involved in the MMR mech-
anism has been shown to inhibit the repair process, potentially
by preventing recombination between the ODN and the targeted
genomic sequence, a phenomenon known as heteroduplex rejec-
tion (Dekker et al., 2003; Pierce et al., 2003; Aarts et al., 2006;
Maguire and Kmiec, 2007; Igoucheva et al., 2008; Papaioannou
et al., 2009). Furthermore, a two- to three-fold increase in fre-
quencies of gene repair has been reported recently in primary
cultures isolated from mdx5cv muscle transfected with targeting
ssODNs in conjunction with a siRNA designed to transiently
downregulate Msh2 expression supporting the implication of the
MMR as one of the mechanisms that controls ssODN-mediated
gene repair inmuscle cells (Maguire et al., 2009). Interestingly, the
authors also failed to detect an effect when Msh2 was downregu-
lated in purified myoblasts maintained in culture for prolonged
period of time suggesting that the MMR may not be the only
mechanism involved in the correction process in myoblasts and
that culturing conditions of these cells may influence the repair
process.
The second phase implicated in the correction process medi-
ated by ODNs, involves the activation of the repair process. Some
studies have implicated the HR pathway through homology-
directed repair (HDR) and non-homologous end-joining (NHEJ)
mechanisms as one of the mechanisms responsible for the cor-
rection induced at the genomic level through evidences that
demonstrate that a portion of the ODN becomes integral part
of the genomic DNA (Radecke et al., 2006; Aarts and te Riele,
2010). However, it is evident that mechanisms other than HR
may be involved in the process catalyzed by ODNs. Among those,
the nucleotide excision repair (NER) pathway appear to play a
role and it was demonstrated that two of the proteins involved
in this repair pathway, XPG and ERCC4, are required to facilitate
ssODN-mediated gene repair, whereas components in the NHEJ
pathway was found to inhibit the correction process (Igoucheva
et al., 2006).
Recent studies aimed at improving the specificity and efficacy
of ssODNs in directing single base alterations at the genomic
level have also evidenced the possibility of recruiting repair mech-
anisms other than HR and NER (Bertoni et al., 2009). The
approach involves the use of ssODNs containing methyl-CpG
sequences and capable of activating the base excision repair (BER)
mechanism through the recruitment of the methyl-CpG bind-
ing domain protein 4 (MBD4) also known as MED1. MBD4
is thought to be responsible for maintaining genome integrity
by recognizing G:T or G:U mismatches at m5CpG sites on
double-stranded DNA (Bellacosa et al., 1999; Hendrich et al.,
1999). In vitro studies have demonstrated that MBD4 can effi-
ciently recognize and hydrolyze G:T or G:U mismatches at hemi-
methylated m5CpG sites as well as G:T and G:U mismatches
in non-methylated CpG sequences (Hendrich et al., 1999). The
introduction of the DNA mismatch is recognized by DNA gly-
cosylases which excise the damaged base from the genomic DNA
creating an apurinic/apyrimidinic site (AP site). The DNA strand
is subsequently processed by specific endonucleases and ligases to
direct the addition of a new cytosine at the AP site and to complete
the repair process using the ssODNs as template (Bertoni et al.,
2009). This new generation of ssODNs was shown to efficiently
correct a single point mutation introduced in a GFP reporter sys-
tem which was stably transfected in myoblasts. The drawback
of using methyl-CpG-modified ssODNs is represented by the
sequence specificity of the mutations that can be targeted by this
approach which limits its broad applications in all genetic defects
(Bertoni et al., 2003, 2009).
THERAPIES FOR DMD USING ODNs TARGETING STEM CELLS
The feasibility of using ssODNs to correct gene defects in SCs
and restore full-length dystrophin expression has recently been
demonstrated by Nick-Ahd et al. In the study, the authors
isolated SCs from the mdx5cv mouse and transfected PNA-
ssODNs targeting the mdx5cv mutation prior to engraftment into
immunocompromised mdx/nude mice (Nik-Ahd and Bertoni,
2014). Clusters of dystrophin-positive fibers were clearly detected
immediately following transplantation and expression of dys-
trophin, resulting from the contribution of donor-derived SCs
that had undergone gene repair, were shown to increase over
time. The work represent the first evidence of the feasibility of
inducing ex vivo gene repair of SCs without compromising the
ability of isolated cells to self-renew following transplantation
(Nik-Ahd and Bertoni, 2014).
More recently, gene editing strategies mediated by ssODNs has
been extended to iPSCs isolated from human skin fibroblasts of
two patients affected by type I spinal muscular atrophy (SMA).
SMA is an autosomal recessive genetic disorder caused by a
genetic defect in the survival motor neuron 1 (SMN1) gene, which
encodes SMN. Loss of SMN protein is thought to be responsible
for the progressive loss of motor neurons which is paralleled by
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the progressive muscle wasting characteristic of SMA patients
(Brzustowicz et al., 1990; Lefebvre et al., 1995; Coovert et al.,
1997). Corti et al used a 75 bp ssODN was used to target and
redirect splicing of the SMN2 gene, a gene paralogous to SMN1
and to induce expression of a protein similar to SMN1. This strat-
egy has previously been shown to partially rescue motor neuron
loss in animal models and is considered a valuable approach to
treat the disease in patients (Lefebvre et al., 1997; Le et al., 2005).
Correction mediated by ssODNs targeting the SMN2 gene was
achieved in approximately 4% of the transfected cells suggesting
frequencies of gene repair similar to those observed in muscle
culture and demonstrating that iPSCs are equally amenable to
gene repair than myoblasts and SCs (Bertoni et al., 2005, 2009;
Maguire et al., 2009; Kayali et al., 2010; Nik-Ahd and Bertoni,
2014). Importantly, when transplanted into the spinal cords of
1-day-old SMA mice, donor-derived motor neuron engrafted in
the anterior spinal cords of transplanted mice and ameliorated
defects in neuromuscular function in SMA mice (Corti et al.,
2012). These results are particularly encouraging as they repre-
sent the first evidence of how gene editing mediated by ssODNs
could have a clinical applicability to disorders other than DMD
demonstrating that the field of gene repair is slowly but steadily
growing toward the development of clinical applications for the
treatment of different neuromuscular disorders.
NUCLEASE-MEDIATED GENE EDITING
During the past 10 years, the field of gene editing has witnessed
a tremendous growth in the number of laboratories interested
in developing corrections strategies using engineered nucleases.
These nucleases are artificial restriction enzymes that can be
designed to target virtually any site in the genome. Their use has
enabled routine reprogramming of prokaryotic and eukaryotic
systems for a variety of applications ranging from site-directed
mutagenesis of bacterial systems, generation of animal models
to study diseases, or simply proof-of-concept studies to demon-
strate the specificity of a biological system. The ability of nucleases
to recognize specific sequences in the genome and introduce a
cleavage at specific sites has been known for almost two decades,
but this technology has boomed only recently. This rapid growth
is in part due to the crescent interest of commercial sources in
developing new products that could be brought to the market
and in part to the recognition of public and government sources
of the potential that this application could have in basic and
translational biology. More recently, nucleases have moved into
preclinical and clinical applications for numerous diseases and
three phase I and phase II clinical trials are on their way in Human
Immunodeficiency Virus (HIV) patients (Tang, 2013a,b; Tebas
and Stein, 2013).
There are three major families of engineered nucleases being
employed in gene editing approaches: zinc finger nucleases
(ZFNs), transcription activator-like effector nucleases (TALENs),
and engineered meganuclease (MNs) (Figure 3). A fourth family
termed clustered regularly interspaced short palindromic repeats
(CRISPR) has been recently developed as an additional approach
to alter genomic sequences at the DNA level (Pauwels et al., 2013).
Despite its early stages of development, the use of CRISPR has
already proven to be a valid alternative to ZFNs, TALENs, and
MNs (Jinek et al., 2012, 2013; Chang et al., 2013; Cong et al., 2013;
DiCarlo et al., 2013; Mali et al., 2013; Wang et al., 2013), but its
potential for the treatment of neuromuscular disorders has yet to
be explored.
The mechanisms of action of nucleases are common to all sys-
tem and rely on their ability to create a double-strand break (DSB)
which is either repaired by NHEJ, or, in the presence of a donor
DNA, can be repaired by HR (Figure 4). Several hurdles still need
to be overcome before this approach can have a wide-spread use
in the context of clinical applications to genetic disorders. Among
those, is the limited level of gene editing frequencies achieved in
cells, the relative difficulty and time consuming process required
to assemble the nucleases in vitro, the need to use viral or plas-
mid vectors to ensure high levels of expression of nucleases in
the nucleus required to achieve an effect and the risk of off-target
mutations that have been associated with their use (as described
in more detail below). Nonetheless, the results reported to date
have clearly proven the validity of using engineered nucleases for
therapeutic purposes.
ZFNs, TALENS, AND MNs
ZFNs are engineered restriction enzymes obtained by fusing a
zinc finger DNA-binding domain to a DNA-cleavage domain
originated from the FokI restriction endonuclease (Figure 3A).
Each zinc finger domain interacts with 3 bps of DNA and can be
engineered to target unique sequences within complex genomes
(Bibikova et al., 2003). The DNA-binding domains of individual
ZFNs typically contain between three and six individual zinc fin-
ger repeats allowing the recognition of sequences of the genome
comprised between 9 and 18 bps respectively. Introduction of the
DSB is mediated by the dimer formed by the association of two
FokI domains. As a result, two ZFNs need to be expressed and
bound to opposite strands of the targeted genomic DNA for the
cleavage to occur (Figure 3A). Furthermore, each FokI domain
needs to be separated by 5–7 bp to allow proper formation of the
FokI dimer. To date, ZFNs have been successfully employed to tar-
get drosophila (Bibikova et al., 2002, 2003; Beumer et al., 2006,
2008, 2013; Bozas et al., 2009), plants (Shukla et al., 2009; Tovkach
et al., 2009; Townsend et al., 2009; Marton et al., 2010; Osakabe
et al., 2010; Zhang et al., 2010; Curtin et al., 2011; Qi et al., 2013),
Caenorhabditis elegans (Morton et al., 2006; Wood et al., 2011),
zebrafish (Doyon et al., 2008; Meng et al., 2008; Foley et al.,
2009a,b; McCammon and Amacher, 2010; Sander et al., 2011b;
Zhu et al., 2011), rat and mouse (Mani et al., 2005; Carbery et al.,
2010; Mashimo et al., 2010; Meyer et al., 2010; Cui et al., 2011;
Osiak et al., 2011; Chou et al., 2012; Hermann et al., 2012; Bhakta
et al., 2013; Shen et al., 2013) and human cells (Alwin et al., 2005;
Urnov et al., 2005; Lombardo et al., 2007; Miller et al., 2007; Perez
et al., 2008; Hockemeyer et al., 2009; Zou et al., 2009; Holt et al.,
2010; Lei et al., 2011; Dreyer and Cathomen, 2012; Handel et al.,
2012; Wang et al., 2012).
One of the major drawbacks that has restricted the wide use of
ZFNs in the research and clinical settings is the limited availability
of DNA-binding domains targeting all trinucleotide combina-
tions and required to guarantee specificity of the ZFN to its target
(Desjarlais and Berg, 1992; Pabo et al., 2001), the high cost of
purchasing engineered zinc-finger units available in proprietary
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FIGURE 3 | Nucleases currently used as gene editing tools for muscle
disorders. (A) Schematic representation of a ZFN dimer bound to its target.
Each ZFN contains the cleavage domain of FokI linked to a series of zinc
fingers each designed to specifically recognize trinucleotide sequences
(colored boxes) flanking the cleavage site. (B) Schematic representation of a
TALEN dimer. Like ZFNs each TALEN contains the catalytic domain of the
FokI endonuclease flanked by modules responsible for the recognition of the
sequence targeted for repair. Unlike ZFNs, however, each modular repeat
binds to a specific bp. Each color represents a module for each of the four
nucleotide bases. (C) Schematic representation of a LAGLIDADG homing
endonuclease (LHE) bound to a DNA target through its catalytic motif.
Sequence specificity toward most DNA targets is usually achieved through
the association or fusion of protein domains from different enzymes to
generate chimeric MNs.
archives (Pearson, 2008) and, even when DNA-binding domains
can be obtained from publically available libraries, the diffi-
culty encountered to assemble and select the ZFNs specific to
the desired sequence (Isalan et al., 1997). These limitations have
been largely overcome by the introduction of a second genera-
tion of engineered nucleases that display similar binding affinity
for their target, but higher specificity and relative ease in assem-
bly. TALENs are artificial restriction enzymes generated by fusing
a TAL effector DNA binding domain to a DNA cleavage domain
(Figure 3B). The DNA-binding domain is generally composed of
repeats ranging in number from 33 to 35 amino acids with the
exception of the 12th and 13th amino acids which vary for each
of the four nucleotides that compose the DNA (Boch et al., 2009;
Moscou and Bogdanove, 2009; Mahfouz et al., 2011). Therefore,
assembly of the TALEN requires the simple combination of the
four possible DNA-binding domains in the order specified by the
sequence of the genomic DNA targeted for repair. Similarly to
ZFNs, a recognition sequence of 14–20 bp is sufficient to confer
specify toward the target site of the genomic DNA, while a sep-
aration of 12–19 bp between FokI domains appears to be ideal
to guarantee efficient dimerization of the catalytic domain of
the nuclease. The relative ease by which these nuclease can be
assembled and the much lower cost of producing or purchasing
custom vectors expressing a specific nuclease has enable gene edit-
ing mediated by TALENs to boom in a relatively short period of
time (Cermak et al., 2011; Mahfouz and Li, 2011; Mahfouz et al.,
2011; Sander et al., 2011a; Tesson et al., 2011; Wood et al., 2011;
Carlson et al., 2012; Li et al., 2012; Liu et al., 2012; Moore et al.,
2012; Tong et al., 2012).
A third class of nucleases has also been implemented as poten-
tial gene editing tools (Figure 3C). MNs (also known as hom-
ing endonucleases) have been developed based on studies that
were originally conducted in yeast and that identified mobile
elements in the genome (HO and I-SceI) encoded by the mito-
chondrial genome and responsible for triggering recombination
events (Orr-Weaver et al., 1981; Kostriken et al., 1983; Jacquier
and Dujon, 1985; Nickoloff et al., 1986; Colleaux et al., 1988).
MNs recognize DNA sequences of 12–40 bp in length and are
classified in five families based on key sequence and structure
motifs. Among those, the LAGLIDADG family is the largest and
best characterized one, and the one currently being used for
designing MNs (Epinat et al., 2013). The initial studies employed
a neomycin resistance reporter gene that was used to demon-
strate the feasibility of targeting NIH3T3 and mouse ESCs (Rouet
et al., 1994; Smih et al., 1995). Since then, MNs have been suc-
cessfully applied to induce mutagenesis, recombination or gene
targeting in bacteria (Cox et al., 2007; Flannagan et al., 2008),
plants (Siebert and Puchta, 2002; Puchta and Fauser, 2013) and
mammalian cells (Thermes et al., 2002; Epinat et al., 2003, 2013;
Grosse et al., 2011; Izmiryan et al., 2011; Munoz et al., 2011;
Menoret et al., 2013). Extensive work conducted on better under-
standing the mechanisms of action and the amino acid structure
of different members of the LAGLIDADG family has enable the
construction of chimeric MNs with improved activity and tar-
getability (Seligman et al., 2002; Arnould et al., 2006; Rosen et al.,
2006; Smith et al., 2006). Nonetheless, the still limited numbers
of sequences that can be targeted combined with the inability
of précising direct the recombination of heterodimers necessary
to induce target specificity mediated by chimeric MNs (Arnould
et al., 2006) has limited its applicability to a large number of
genetic disorders.
APPLICATION OF ENGINEERED NUCLEASE FOR THE TREATMENT OF
MUSCLE DISORDERS
The use of engineered nucleases to precisely direct genomic
alterations in specific genes known to cause muscle disorders
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FIGURE 4 | Gene editing using nucleases.Upon introduction into the cell and
following recognition of the region of the genomic DNA targeted for repair, the
binding domains of the nucleases associate and generate a DSBwhich triggers
the activation of specific repair mechanisms. In the absence of donor DNA
sequences, the break is repaired by the NHEJ repair pathway by cleaving
non-compatible overhang sequences and by joining the ends of the cleaved
sequences (targeted deletion). This usually results in deletions of one or more
bases (indels). Depending on the type of mutation targeted for repair, these
deletions can lead to either, the inactivation of the gene or to the expression of
in-frame transcripts encoding for shorter, although still functional proteins.
Introduction of single base alterations can only occur in the presence of a donor
DNA containing the desired sequence (targeted correction). The process is
directed by the HR pathway and requires the exchange of DNA sequences from
the donor DNA to the genomic DNA targeted for repair.
has so far been limited to proof-of-concept studies and have
focused primarily on determining their applicability for the treat-
ment of DMD (Chapdelaine et al., 2010; Rousseau et al., 2011;
Benabdallah et al., 2013; Ousterout et al., 2013). MNs and ZFNs
have been used to test the feasibility of activating the NHEJ
repair mechanism and of restoring the normal reading frame
of a dog microdystrophin gene containing a frame-shift muta-
tion (Chapdelaine et al., 2010; Rousseau et al., 2011). The ability
of MNs to induce indels in the dystrophin locus has also been
demonstrated through studies aimed at determining the effect
of chromatin accessibility on genome editing mediated by MNs
(Daboussi et al., 2012). In this study, Daboussi et al designed 37
MNs capable of cleaving different genomic targets. Among those,
5 MNs were shown to efficiently target intronic regions of the
dystrophin gene. Although the study was not designed to assess
the feasibility of using MNs to restore dystrophin expression, it
clearly demonstrated that the dystrophin locus is amenable to
gene editing mediated by MNs paving the way for further work
aimed at developing effective gene repair strategies to DMD using
MNs.
Nuclease-mediated editing of dystrophin gene defects has been
recently demonstrated in human cells. TALENs have been tested
in primary dermal fibroblasts isolated from a DMD patient har-
boring a deletion of exons 46–50 (46–50) and have been used to
induce targeted deletions of exon 51 to restore the coding reading
frame of the dystrophin gene (Ousterout et al., 2013). Clonal
analysis identified a clone with an NHEJ event expected to cor-
rect the dystrophin reading frame. When transdifferentiated into
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myoblasts following ectopic expression of MyoD, cells generated
from the clone were shown to form myotubes expressing a dys-
trophin protein of a molecular weight identical to that predicted
as a result of the expression of an in frame transcript lacking exon
46 through 50 of the dystrophin mRNA. The robustness of the
approach was further confirmed in immortalized myoblast cells
lines isolated from twoDMDpatients with a deletion of exons 48–
50 (48–50) also treatable by the same pair of TALENs used to
correct the 46–50 fibroblasts. In addition to confirm the ability
of nucleases of targeting the humanDMD gene, these studies have
also established the feasibility of using TALEN-mediated NHEJ to
target and correct dystrophin gene defects caused by large dele-
tions further extending the applicability of the approach to the
majority of the mutations causing DMD.
DRAWBACKS AND LIMITATIONS OF GENE EDITING
MEDIATED BY ODNs AND ENDONUCLEASES
As any technology currently being tested and optimized for the
treatment of genetic disorders, limitations do exist that may ulti-
mately preclude the use of ODNs or engineered nucleases from
entering the clinic for the treatment of DMD. In the case of
ODNs, perhaps the major drawback is the low efficiency of the
correction process achieved to date. While the use of specific
modifications inserted on the oligonucleotides to stabilize the
structure of ssODNs (Kayali et al., 2010) or those used to recruit
specific repair mechanisms (Bertoni et al., 2009) have proven to
significantly increase the gene correction frequencies achieved in
muscle in vitro and in vivo, the frequencies obtained remain low.
Other factors are likely to influence the clinical applicability of
ODNs including the possibility to induce mutations at regions of
the genome different from that targeted for repair, a phenomenon
that has not been studied in detail. Additional parameters such as
possible toxicity of the ODNs once introduced into patients will
also have to be examined.
One of the limiting factors that preclude the use of engineered
nucleases, particularly for clinical applications, is represented by
the inability to efficiently control the level of expression of the
nucleases once delivered to the cell and by the fact that certain
endonucleases such as ZFNs and TALENs require the formation
of dimers to be active which implies the use of at least two vec-
tors to efficiently express each endonuclease. To date, delivery of
endonuclease into the cells has employed, for the most part, the
use of plasmid vectors. Although this method of delivery result in
efficient expression of the vectors sustained only for a short period
of time, potentially the time needed for the nucleases to induce
the desired genomic alteration, the level of expression achieved
cannot be easily controlled and the efficiency of delivery is lim-
ited particularly when targeting stem cells or muscle progenitor
cells. An alternative approach is to use lentiviral vectors which
have been shown to efficiently transduce stem cells and to be able
to achieve high levels of transgene expression. Although effective,
these vectors are known to randomly integrate into the genome
and therefore they can potentially bemutagenic. This problem has
been recently addressed through extensive studies aimed at better
characterizing the sequences encoded by the lentiviral vector that
direct the recombination process and has led to the development
of a new generation of lentiviral vectors unable of integrating
(Cornu and Cathomen, 2007; Lombardo et al., 2007). Although
safer, these vectors can only achieve limited levels of expression
into cells which have been associated with significant lower lev-
els of gene correction frequencies. Promising results have been
obtained using adenoviral vectors (Perez et al., 2008; Holkers
et al., 2013) and adeno-associated virus vectors which have been
shown to drive efficient expression of the nucleases into cells
(Porteus et al., 2003; Gellhaus et al., 2010; Metzger et al., 2011).
Nonetheless, these vectors still require systems to control their
expression once introduced into the cell.
An alternative to the use of viral vectors is the introduction
into the cell of mRNA encoding for the nuclease (Geurts et al.,
2010; Meyer et al., 2010; Zou et al., 2011) or purified nuclease
proteins (Gaj et al., 2012). This method, however, has shown only
limited efficacy and is associated with higher costs of production
and purification of the endonucleases at the doses required to
achieve significant effects.
A major concern that limits the use of endonuclease partic-
ularly in the context of therapeutic applications, is the potential
off-target effects that have been associated with their use. These
effects appear to be related, for the most part, to the lack of bind-
ing specificity of the DNA-binding domain toward its recognition
sequence (Bibikova et al., 2002; Olsen et al., 2009). As such, cleav-
age of regions other than those targeted for repair may result in
the generation of indels that, once repaired through NHEJ events,
could lead to the inactivation of genes. If the inactivation occurs
in genes responsible for muscle stem cells maintenance or nec-
essary for the proper function of muscle progenitor cells poses
serious safety concerns. Future applications of gene editing target-
ing and employing stem cells for therapeutic purposes will have
to be further refined and issues of toxicity as well as possible side
effects will have to be evaluated in detail so as to guarantee safe
and long lasting effects.
FUTURE OF GENE EDITING STRATEGIES IN MUSCLE STEM
CELLS
Several parameters need to be considered and optimized before
we can reach the stage of designing clinical trials using gene edit-
ing approaches that specifically target muscle stem cells. First
among all, is the efficacy of the approach being used and the ben-
efits that can be achieved by the different systems being employed.
Approaches aimed at correcting stem cells ex vivo have clear
advantages over systems that target stem cells in situ (Figure 1).
First, delivery of ODNs or nucleases in cells maintained in culture
it is easier to accomplish as it can rely on both chemical as well
as physical methods of delivery. For instance, the use of chemical-
based reagents such as Lipofectamine™ 2000, Fugene® HD and
other of transfection reagents currently in the market, as well as
electroporation devices such as AmaxaNucleofector™ andNeon®
Electroporation System have proven to be effective in deliver-
ing naked DNA, including ssODNs as well as plasmids encoding
nucleases into muscle progenitor cells, SCs, and ESCs (Bertoni
and Rando, 2002; Bertoni et al., 2003, 2005; Dekker et al., 2003,
2006; Pierce et al., 2003; Aarts et al., 2006; Flagler et al., 2008;
Kayali et al., 2010; Corti et al., 2012; Fontes and Lakshmipathy,
2013). Additionally, viral vectors can be used to express nucle-
ases in cases where chemical and electroporation methods pose
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a challenge. Another advantage of targeting and correcting stem
cells ex vivo, is represented by the fact that cells that have under-
gone repair can be selected, expanded in culture and characterized
to ensure that they are safe to use in patients. Importantly, cells to
be transplanted into muscle can undergo quality checks to ensure
they are devoided of off-target mutations introduced by the ODN
or the nuclease in region of the genome other than that targeted
for repair. Great progress has been made toward the develop-
ment of technologies capable of sequencing the entire genome
or of studying changes in gene expression at a single cell level.
These technologies are likely to become integral part of study
design for future clinical trials and will be instrumental to the
progress of gene editing technologies toward a safe and effec-
tive approach to treat muscle disorders. Finally, clones obtained
following selection and expansion can potentially be stored over
prolonged periods of times, virtually the lifetime of the patient,
and could serve as a reservoir of cells to be used in the event that
repeated administrations are required.
The major drawback of ex vivo approaches is represented by
the difficulty encountered in delivering stem cells into skeletal
muscles and the need to target a large number of muscles for
the therapeutic approach to be clinically relevant. So far, most
of the studies aimed at determining the efficacy of the geneti-
cally modified cells to restore muscle function have focused on
delivering the cells intramuscularly. Although perfectly suitable
for applications aimed at studying the efficacy of the cells being
introduced into tissues to engraft and to regenerate muscle, this
approach is not applicable in a clinical setting due to the number
of injections that would be required to achieve functional effects
in patients. Clinical applications to muscle disorders are likely to
rely on the use of procedures capable of deliver genetically mod-
ified cells systemically. Intravenous or intrarterial injections have
been successfully used to deliver Sca-1+CD34+ (Torrente et al.,
2001) and CD133+ (Torrente et al., 2004) muscle derived stem
cells, mesoangioblasts (Sampaolesi et al., 2006), and pericytes
(Dellavalle et al., 2007), but appear to have limited applicability
with other cell types. Factors that can promote migration, sur-
vival, and engraftment of cells following administration are likely
to have important implications for the success of cell-mediated
regenerative approaches for the treatment of neuromuscular dis-
eases. Some success has already been achieved following pretreat-
ment of mesoangioblasts with stromal-derived factor-1 (SDF-1)
and tumor necrosis factor-α (TNF-α) prior to administration of
mesoangioblasts into dystrophic mice (Galvez et al., 2006) and,
more recently using inhibitors of junctional adhesion molecule-A
(JAM-A) expression, a small immunoglobulin that is located at
endothelial and epithelial cell junctions (Giannotta et al., 2014).
Direct delivery of ODNs or nucleases into skeletal muscles may
represent a valuable alternative to transplantation of genetically
modified cells. In general, this approach will only be able to tar-
get endogenous muscle stem cells that are actively participating
to the regeneration process such as SCs. Furthermore, it would
be applicable only to patients that are at an early stage during the
disease process before the reservoir of cells capable of regenerating
muscles is exhausted or before their regenerative capacity is com-
promised as a result of the continue activation typical of muscles
that undergo repeated rounds of degeneration and regeneration.
Several methods of delivery are currently being optimized and
tested for their ability to distribute ODNs and nucleases into dif-
ferent organs and tissues following systemic administration. In
the case of ODN-based therapies some success has been achieved
using trans-activator of transcription (Tat) protein of the HIV
(Frankel and Pabo, 1988; Green and Loewenstein, 1988; Green
et al., 1989; Brooks et al., 2005; Bechara and Sagan, 2013). More
recently, efforts have been directed toward the identification of
short peptide sequences that could be linked to ODNs and used to
enhance their uptake through mechanisms of endocytosis and/or
direct translocation across the plasma membrane (Joliot et al.,
1991; Bechara and Sagan, 2013; Betts and Wood, 2013; Moulton,
2013; Regberg et al., 2013). Some success has been achieved using
ODNs tagged to cell penetrating peptides (CPPs) which have been
shown to successfully target and distribute ODNs into myofibers
following systemic administration (Lescop et al., 2005; Moulton
et al., 2007; Ivanova et al., 2008; Wu et al., 2008; Yin et al., 2008;
Betts and Wood, 2013). Moreover, the use of CPPs has been
implemented in gene editing technologies aimed at enhancing
delivery of engineered nucleases with promising results further
highlighting the potential of using peptide as carriers to enhance
delivery (Nain et al., 2010; Puria et al., 2012; Chen et al., 2013).
However, most of the studies thus far have been focused on
targeting myofibers and little is known on the ability of CPPs
to penetrate SCs or other types of muscle stem cells following
systemic delivery.
The main drawback of directly delivering systemically ODNs
or nucleases into muscles is represented by the inability to control
the repair process once the therapeutic agent reaches it targeted
stem cell. As a result, issues of toxicity, off-target effects, and
low frequencies of gene repair may limit the beneficial effects
achieved. Studies aimed at further refine the efficacy and speci-
ficity of the repair process mediated by ODNs or nucleases is likely
to have important implications for the success of gene editing
approaches.
Independently from the approach used to correct the genetic
defect and whether restoration of the missing protein is achieved
through delivery of genetically modified cells ex vivo or sys-
temic administration of gene editing tools in situ, other factors
may hamper the efficacy and stability of the repair process.
Considerations should be given to possible immune response
toward the protein being restored as the result of the therapeutic
application. Preconditioning of patients using immunosuppres-
sive reagent as well as administration of chemotherapeutic drugs
that are toxic to proliferating cells may be necessary to ensure
efficient cell engraftment and rapid clonogenic growth of the
transplanted cells.
SUMMARY AND CONCLUSIONS
The past decade or so has seen an exponential growth in the
development of therapeutic applications for muscle disorders
specifically designed to target stem cells. Clinical trials are cur-
rently undergoing to test the feasibility and efficacy of restoring
dystrophin expression in skeletal muscles of DMD patients fol-
lowing systemic administration of mesoangioblasts highlighting
the fact that the field is rapidly advancing toward clinical appli-
cations for this disease. Approaches aimed at using the patient
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own stem cells as source for the transplantation procedures has
clear advantages over those using heterologous sources of stem
cells. As such, it is likely that gene editing approaches will become
integral part of future applications to treat muscle disorders using
genetically modified cells.
Additional parameters will have to be taken into account
and defined before these approaches can enter into the clinic.
For instance, gene editing strategies targeting stem cells ex vivo
will require to refine culturing techniques to ensure that, once
explanted, muscle stem cells can be efficiently propagated in vitro
while maintaining maximal regenerative potential. Furthermore,
a better understanding of the mechanisms that regulate stem-cell
properties will help redefine and select a specific population of
cells that is safe to use in patients without compromising the ben-
eficial effects that can be achieved using the approach. Along the
same line, the development of new delivery systems or vectors
capable of targeting muscle stem cells in situ will be a key to the
optimization of gene editing strategies. Ultimately, a key compo-
nent of preclinical and clinical studies will remain the efficacy and
safety of the approach being employed. The trials currently under
way for muscle disorders as well as other genetic diseases and the
clinical trials that are planned to start within the next few years
will be instrumental in determining the key parameters necessary
to achieve sustained effects in patients and to ensure the safety and
efficacy of the approach being employed. Despite the early stages
of gene editing approaches aimed at targeting and correcting stem
cells for the treatment of muscle disorders, the results obtained to
date are encouraging. Collaborations among different laborato-
ries interested in pursuing these technologies for the treatment of
inherited genetic disease affecting muscle could result in advanc-
ing gene editing strategies more rapidly and more efficiently into
the clinic.
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